In a quick turnaround, CMS rescinded its September 26, 2022 memo and has decided it will continue to exercise its enforcement discretion under CLIA for the duration of the COVID-19 public health emergency for the use of SARS-CoV-2 molecular and antigen point of care (POC) tests on asymptomatic individuals outside of the test’s authorization.